<DOC>
	<DOCNO>NCT00741260</DOCNO>
	<brief_summary>This world wide phase 1/2 , open-label , study neratinib combination capecitabine , conduct 2 part . In Part 1 , 3 9 subject solid tumor enrol dose group combination neratinib capecitabine . Each subject participate 1 dose group . Additional subject may include dose level ass safety tolerability dose level . In Part 2 , 60 subject erbB-2 positive metastatic breast cancer receive treatment combination neratinib capecitabine maximum tolerate dose level , determine Part 1 . In addition 20 subject prior lapatinib exposure enrol Part 2 . Depending safety activity profile observe dose escalation phase , dose select Part 2 may adjust , appropriate . In case one test article combination discontinue due intolerance test article administer alone . The primary objective Part 1 assess safety tolerability , define Maximum tolerate dose ( MTD ) neratinib combination capecitabine subject advance solid tumor . The primary objective Part 2 study confirm MTD determine Part 1 . The secondary objective Part 1 collect information preliminary anti-tumor activity combination neratinib capecitabine . Secondary objective Part 2 collect pharmacokinetic information obtain additional efficacy data , Objective Response Rate , subject erbB-2 positive breast cancer treat MTD neratinib + capecitabine .</brief_summary>
	<brief_title>Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Part 1 : confirm pathologic diagnosis solid tumor curable available therapy neratinib plus capecitabine reasonable treatment option . Part 2 : confirm histologically and/or cytologically confirm diagnosis breast cancer , metastatic locally advance . Part 2 : erbB2 gene amplify tumor ( FISH CISH ) erbB2 overexpression ( IHC 3+ , IHC2+ FISH CISH confirmation ) , base local testing , base centralized FISH test prior day 1 . Part 2 : disease progression follow least 1 prior trastuzumab contain treatment regimen ( least 6 week ) metastatic locally advanced disease . ( Prior adjuvant trastuzumab allow require ) . A 2 week period require last dose trastuzumab treatment first dose test article . Prior treatment taxane neoadjuvant , adjuvant , locally advanced , and/or metastatic disease treatment set . Parts 1+2 : At least 1 measurable lesion define RECIST criterion . Parts 1+2 : LVEF within institutional range normal measure multigated acquisition ( MUGA ) echocardiogram ( ECHO ) . Part 2 : prior treatment capecitabine , lapatinib ( 20 subject prior lapatinib exposure enrol ) erbB2 target agent except trastuzumab . Treatment erbB2 target therapy must exceed 2 week ( 14 day ) order exclusionary . Part 2 : prior treatment anthracyclines cumulative dose doxorubicin great 400 mg/m2 , epirubicin dose great 800 mg/m2 , equivalent dose anthracyclines . Parts 1+2 : Subjects bone site disease . Parts 1+2 : Active uncontrolled symptomatic central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , and/or progressive growth . Subjects history CNS metastases cord compression allowable consider definitively treated anticonvulsant steroid least 4 week first dose test article . Parts 1+2 : Any cancer within 5 year prior screen exception adequately treat cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>erbB2+ breast cancer</keyword>
	<keyword>prior Herceptin</keyword>
	<keyword>metastatic</keyword>
</DOC>